Royal Philips told investors this week that delays in restarting production at its Philips Healthcare division's CT manufacturing facility in Cleveland will result in lower than expected fourth-quarter earnings, according to a report in the Wall Street Journal.
Philips had suspended production at the facility last year after the U.S. Food and Drug Administration (FDA) questioned manufacturing controls. Issues with restarting production will also hurt 2014 earnings by an expected 225 million euros ($266 million U.S.), up from a previous estimate of 180 million euros ($216 million), according to the Wall Street Journal.
In good news, Philips has again begun shipping its Brilliance iCT product from the Cleveland facility after its quality-management system received external certification, according to the article.
![Images show the pectoralis muscles of a healthy male individual who never smoked (age, 66 years; height, 178 cm; body mass index [BMI, calculated as weight in kilograms divided by height in meters squared], 28.4; number of cigarette pack-years, 0; forced expiratory volume in 1 second [FEV1], 97.6% predicted; FEV1: forced vital capacity [FVC] ratio, 0.71; pectoralis muscle area [PMA], 59.4 cm2; pectoralis muscle volume [PMV], 764 cm3) and a male individual with a smoking history and chronic obstructive pulmonary disorder (COPD) (age, 66 years; height, 178 cm; BMI, 27.5; number of cigarette pack-years, 43.2, FEV1, 48% predicted; FEV1:FVC, 0.56; PMA, 35 cm2; PMV, 480.8 cm3) from the Canadian Cohort Obstructive Lung Disease (i.e., CanCOLD) study. The CT image is shown in the axial plane. The PMV is automatically extracted using the developed deep learning model and overlayed onto the lungs for visual clarity.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/03/genkin.25LqljVF0y.jpg?auto=format%2Ccompress&crop=focalpoint&dpr=2&fit=crop&h=167&q=70&w=250)
